latest news releases from the newsroom
Rockwell Medical, Inc.
Rockwell Medical Technologies, Inc. Announces Updated DSMB Interim Results; No Safety Issues Reported
WIXOM, Mich., April 16, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency anemia, reported today that the independent Data Safety Monitoring Board (DSMB) providing oversight for the ongoing SFP Phase 2b dose-range study reviewed the unblinded cumulative interim study data and informed the Company that it has identified no safety concerns. The DSMB also determined there is no need to add the highest dose group of 20 ug/dl and recommended continuation of the study with the current five dose groups.